Revolutionizing Opioid Use Disorder Treatment: Unveiling BRIXADI and Beyond

Greetings, fellow seekers of healthcare knowledge and future healthcare leaders! Today, we're embarking on a journey into a realm that's shaping the future of addiction treatment – a sphere where our roles as healthcare professionals will play a pivotal role. As we navigate the dynamic world of pharmaceuticals, it's essential to stay abreast of innovations that are transforming the landscape of opioid addiction treatment.

---

Understanding Opioid Use Disorder (OUD):

Image from: https://www.fiercepharma.com/pharma/braeburns-long-acting-brixadi-cleared-treat-opioid-use-disorder

Opioid Use Disorder (OUD) is a complex medical condition that affects millions worldwide. Individuals grappling with OUD engage in compulsive opioid use despite the severe consequences that follow. The impact of OUD reverberates through physical, emotional, and social well-being. Staggering statistics reveal over 130 overdose deaths per day in the United States alone, underscoring the urgency to reimagine addiction treatment.

The Current Treatment Landscape:

Traditional approaches to OUD treatment typically encompass daily oral medications, counseling, and behavioral therapies. While these methods have yielded positive outcomes for many, they bear certain limitations. For instance, the administration of transmucosal buprenorphine-containing products demands frequent dosing, potentially hindering patient adherence and overall progress.

Enter BRIXADI™:

A Paradigm Shift in OUD Treatment: In this transformative landscape, BRIXADI™ (buprenorphine), a groundbreaking extended-release subcutaneous injection developed by Braeburn, emerges as a beacon of hope. Departing from convention, BRIXADI offers both weekly and monthly dosing options, ushering in a new era in OUD treatment. Its promise lies in the principles of convenience, efficacy, and patient-centricity.

What Sets BRIXADI Apart?

1. Flexible Dosing Regimens: BRIXADI offers patients the autonomy to opt for weekly or monthly injections. This flexibility empowers them to customize their treatment to align with their personal preferences and schedules.

2. Smooth Transition: Individuals currently using transmucosal buprenorphine-containing products can transition seamlessly to BRIXADI Weekly or Monthly. This ensures uninterrupted care and enhances the overall patient experience.

3. Research-Powered Efficacy: The impact of BRIXADI is validated by a rigorous Phase 3 clinical trial. Notably, the trial not only demonstrated non-inferiority to existing treatments but also showcased superiority against sublingual buprenorphine/naloxone (SL BPN/NX) in specific endpoints.

4. Addressing Safety: Prioritizing patient safety, BRIXADI incorporates a Boxed Warning and operates within the BRIXADI Risk Evaluation and Mitigation Strategy (REMS). This comprehensive approach equips healthcare providers to administer the treatment securely. The program will require healthcare providers to be certified before dispensing the drug.

5. Affordability: The drug's cost for most patients will be $10 or lower, as communicated by a representative from the company to Fierce Pharma.

Beyond BRIXADI:

Navigating the Competitive Landscape: While BRIXADI is a trailblazer in OUD treatment, it doesn't stand alone in the field. Competing brands like Sublocade by Indivior Inc. (buprenorphine extended-release) and Zubsolv by Orexo U.S. Inc. (buprenorphine/naloxone sublingual tablet) offer alternative formulations and approaches. Sublocade, for instance, provides a monthly subcutaneous injection, while Zubsolv presents a sublingual tablet – catering to diverse patient preferences and needs.

Numbers That Matter:

• Opioid overdose deaths in the U.S. surpassed 93,000 in 2020, marking a record high.

• Over 10 million people aged 12 or older reported misusing opioids in the past year in the United States, emphasizing the widespread impact of opioid addiction on society.

• BRIXADI demonstrated non-inferiority to SL BPN/NX in the Phase 3 trial (16.9% vs. 14.0%, respectively; p<0.001).

• In the same study, BRIXADI showcased superiority based on the cumulative distribution function of negative opioid assessments from week 4 to week 24 (p=0.004).

Embracing the Future:

As the opioid crisis persists, BRIXADI's FDA approval and its contemporaries cast a hopeful light. By offering extended-release options tailored to patient preferences and lifestyles, these treatments redefine the addiction therapy landscape. The journey ahead entails advocating for equitable access, patient education, and interdisciplinary collaboration to maximize their impact.

In Conclusion:

BRIXADI and its competitors stand at the forefront of transforming OUD treatment, representing a pivotal moment in our journey to combat the opioid crisis. As we navigate this evolving healthcare realm, let's stay vigilant, informed, and dedicated to crafting a future where addiction treatment isn't just effective, but also tailored to the unique path of each individual's recovery.

Coming Soon:

• Stay tuned for an in-depth interview regarding OUD with Dr. Robert Jensen, PharmD (MSL @ Braeburn) on the Insight Into Industry Platform!

• IN3 Link-Tree: linktr.ee/insightintoindustry

Subscribe

---

References:

1. Centers for Disease Control and Prevention. (2021). Understanding the Epidemic. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html

2. Braeburn. (2023). BRIXADI™ (buprenorphine) extended-release subcutaneous injection prescribing information.

3. Lofwall, M., et al. (2022). Efficacy and safety of weekly and monthly subcutaneous BRIXADI (buprenorphine) injection in adults with moderate to severe opioid use disorder: A Phase 3 randomized trial. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(22)00277-6

4. Indivior UK Limited. (2023). SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use prescribing information. Retrieved from https://www.sublocade.com/pdf/prescribing-information.pdf

5. Orexo US, Inc. (2022). ZUBSOLV® (buprenorphine and naloxone) sublingual tablets, CIII prescribing information. Retrieved from https://www.zubsolv.com/-/media/Files/Zubsolv/US/pdf/prescribing-information.pdf

Disclaimer: The information provided in this blog post is for educational purposes only and should not be considered medical advice. Consult a healthcare professional for personalized medical guidance and treatment options.